Pleural metastasis is one of the most common complications in lung cancers. However, no effective therapy for pleural metastasis has been established thus far. We have constructed a metastatic model of non-small cell lung cancer (NSCLC) by injecting human NSCLC cell lines directly into the left pleural cavity of BALB/c nude mice. Because this model is easy to construct and the results are reproducible, we used this model for a preclinical evaluation of gene therapy for pleural metastasis of NSCLC. We took the novel approach of in vivo lipofection of a suicidal gene to lung cancer cells metastasized to the pleural cavity. A human lung cancer cell line, PC14, was inoculated into the pleural cavity of nude mice. After 1 day, a herpes simplex virus thymidine kinase gene expression plasmid was injected intrapleurally as a DNA-liposome complex, and ganciclovir was subsequently administered for 8 days. The survival rates of the ganciclovir-treated group were significantly better than those of the control groups. Flow cytometric analysis using a green fluorescent protein expression plasmid suggested that the transfection efficiency in the pleural cavity was 13.6%. Moreover, due to a bystander effect with PC14 cells, 10% of the gene transfer efficiency was sufficient to eradicate or suppress pleural metastasis. This preclinical study suggests the therapeutic feasibility of an in vivo lipofection-based suicidal gene/prodrug strategy for pleural metastasis of NSCLC.
M alignant pleural effusion and pleural metastasis are major causes of significant morbidity in patients with advanced malignancies. 1 Lung cancer is the most frequent cause of malignant pleural effusion in all malignancies (ϳ35% overall). 2, 3 In patients with chemosensitive diseases such as lymphoma and small cell lung cancer, a systemic therapy may bring about a resolution of the effusion. However, for most patients with nonsmall cell lung cancer (NSCLC), another means of managing malignant pleural effusion is necessary, because NSCLC is often resistant to chemotherapy. Repeated needle thoracentesis can provide temporary symptomatic relief, but most effusions reaccumulate within 1-3 days. 4 Pleurectomy is effective but carries a high morbidity (23%) and mortality (10%). 5 Although the most common therapy for malignant pleural effusions in NSCLC is a tube thoracotomy followed by chemical pleurodesis by intrapleural instillation of a sclerosing agent, effective agents for pleurodesis are not available. 6 Thus, no effective therapy has been established thus far to alleviate this devastating and often fatal end-stage condition.
Suicidal gene therapy with the herpes simplex virus thymidine kinase (HSV-TK) gene and the prodrug ganciclovir (GCV) has introduced new possibilities for the treatment of several malignancies. 7 GCV is triphosphorylated through phosphorylation by HSV-TK and host cellular kinases, and then acts as a chain terminator and interferes with DNA synthesis in the replicating cells. This eventually will cause cell growth arrest or cell death. 8 In animal models, a successful antitumor effect of HSV-TK/GCV treatment has been demonstrated. 9, 10 HSV-TK/GCV therapy showed remarkable results for rats with transplanted brain tumors, which developed in an anatomically, physiologically, and immunologically distinct and unique closed space, the cranial cavity. 7,10 -13 The efficacy and safety of lipofection-based HSV-TK/ GCV therapy to pancreatic cancer cells disseminated in the mouse peritoneal cavity has been also reported. 14 Preclinical studies and phase I clinical trials in NSCLC have shown that genes can be delivered to lung cancer cells with sufficient efficiency by a direct intratumoral (i.t.) injection to mediate tumor regression. [15] [16] [17] We have constructed a metastatic model of NSCLC by injecting human NSCLC cell lines directly into the pleural cavity of BALB/c nude mice. 18 Using this model, we show a novel approach of in vivo introduction of a suicidal gene to lung cancer cells. We found that pleural metastases in nude mice were successfully treated by a direct intrapleural injection of an HSV-TK expressing plasmid-liposome complex followed by GCV treatment. Possible applications of this method for the treatment of pleural metastasis in NSCLC will be discussed.
MATERIALS AND METHODS

Cell lines and establishment of HSV-TKtransduced clones
A human lung adenocarcinoma cell line, PC14, was used in this study. The cells were maintained in RPMI 1640 medium (Nissui Pharmaceutical, Tokyo, Japan) supplemented with 10% fetal calf serum on plastic and were incubated in 5% CO 2 /95% air at 37°C.
The pCtkN2 vector used in this study is an HSV-TK expression plasmid under a potent hybrid promoter CAG, which consists of the cytomegalovirus immediate early enhancer sequence and the chicken ␤-actin/rabbit ␤-globin hybrid promoter.
14 The pCtkN2 vector was transfected into PC14 cells in vitro using cationic liposome formulated by 1,2-dimyristyloxypropyl-3-dimethyl-hydroxy-ethyl ammonium bromide and cholesterol (DMRIE-C) (Life Technologies, Rockville, Md). After 60 hours of transfection, G418 selection was imposed (800 g/mL; Geneticin; Life Technologies). G418-resistant cells were cloned with stainless steel cylinders and maintained in the medium containing G418. Cell clones resistant to G418 were assayed for the expression of HSV-TK mRNA by Northern blot analysis, and the amount of HSV-TK and ␤-actin mRNA was quantified by densitometric analysis. RNA loading levels were standardized with respect to the amount of ␤-actin mRNA. The levels of HSV-TK mRNA expression in clones were relative to the level of HSV-TK in PC14-TK-16 cells.
GCV sensitivity of HSV-TK-transduced cells in vitro
HSV-TK-transduced PC14 cells were seeded at 2.0 ϫ 10 4 cells/well on six-well plates in duplicate. After 24 hours of culture, a fresh medium containing various concentrations of GCV (0 -100 M) (Nippon Syntex Laboratories, Tokyo, Japan) was added to the respective wells. The GCV-containing medium was changed daily for 5 days, and the cells were counted by the trypan blue exclusion method. From the cell killing curve, the 50% inhibitory concentration (IC 50 ) was determined as the GCV concentration that killed 50% of the cell population.
GCV sensitivity of subcutaneously (s.c.) injected HSV-TK-transduced cells in vivo Cells (1 ϫ 10 7 ) in a 0.2-mL suspension were injected s.c. into the flanks of BALB/c nude mice to generate s.c. tumors. GCV treatment was started after the tumors grew to 0.5-0.6 cm in diameter. GCV (50 mg/kg) was intraperitoneally (i.p.) injected once a day for 14 days. The tumor size was monitored until the mice became moribund or monitored for Յ140 days by measuring length and width three times per week with a caliper; tumor size was then converted to volume (V) according to the following formula: V ϭ length ϫ (width) 2 ϫ 1/2. The size of the tumors produced by HSV-TK-transduced clones was compared with that produced by parent PC14 cells using Fisher's exact test.
GCV sensitivity of intrapleurally injected HSV-TKtransduced cells in vivo
Previously, we constructed a pleural metastatic model of NSCLC by injecting human NSCLC cell lines directly into the left pleural cavity of BALB/c nude mice. 18 First, the mice were anesthetized with ethyl ether and put in a position of right lateral decubitus. The HSV-TK-transduced cells were injected into the left pleural cavity of the mice using a syringe with a 27-gauge needle. The needle was advanced ϳ5 mm through the chest wall into the pleural cavity, and 2.0 ϫ 10 6 cells were dispersed into the pleural cavity in a final volume of 0.2 mL of serum-free medium. The i.p. administration of GCV was started at 24 hours after injection of the cells at the dose of 50 mg/kg body weight every 12 hours for 8 days. When the mice became moribund with the symptom of elevated breathing rates, they were sacrificed by exsanguination from the vena cava inferior under deep ether anesthesia. Differences in survival among mice receiving an injection of HSV-TK-transduced and untransduced cells were analyzed for statistical significance using the log-rank test.
Intrapleural lipofection of HSV-TK gene and GCV treatment
We injected 2.0 ϫ 10 6 PC14 parent cells into the pleural cavity of 15 female BALB/c nude mice (day 0). For the treatment group, five mice were injected into the pleural cavity with 30 g of the HSV-TK expression plasmid, pCtkN2, complexed with 75 L of DMRIE-C starting at day 1 for a total of three times at 24-hour intervals. GCV treatment was started 24 hours after the first injection of DNA-liposome complex. GCV at the dose of 50 mg/kg body weight was injected i.p. every 12 hours for 8 days (Fig 1A) . The remaining 10 mice receiving PC14 injections constituted two different control groups as follows: Five mice were injected in the pleural cavity three times with 30 g of pCtkN2 complexed with 75 L DMRIE-C followed by an injection of 200 L of saline instead of GCV for 8 days ( Fig  1B) ; the other five mice were not treated at all after the injection of PC14 cells (Fig 1C) . Differences in survival among the three groups of mice were analyzed for statistical significance using the log-rank test. 
Bystander effect of HSV-TK-transduced cells
The cell killing mediated by the bystander effect in vitro was examined using PC14 cells cocultured with various percentages (0%, 1%, 3.3%, 10%, 33%, and 100%) of the HSV-TKtransduced PC14 cells, PC14-TK-14. Cells were seeded at 2.0 ϫ 10 4 cells/well in six-well plates in duplicate; after 24 hours of culture, GCV was added to the culture medium at a final concentration of 10 M. The GCV-containing medium was changed daily for 5 days, and the cells were counted by the trypan blue exclusion method. The percentage of cell killing was expressed by the number of GCV-treated cells per number of untreated cells.
To study the bystander effect in vivo, tumors were generated by injecting 0.2 mL of cell suspension containing 1 ϫ 10 7 of various ratios of transduced and untransduced PC14 cells into the flanks of BALB/c nude mice. When the size of the s.c. tumors reached 0.5-0.6 cm in diameter, GCV at 50 mg/kg body weight was administered i.p. every 24 hours for 14 days. Tumor size was monitored three times per week until the mice became moribund or monitored for Յ140 days. The size of the tumors produced by PC14 cells mixed with various percentages of PC14-TK-14 cells was compared with that produced by parent PC14 cells using Fisher's exact test.
The bystander effect in the pleural cavity was examined as follows: A total of 2.0 ϫ 10 6 of various ratios of transduced and untransduced PC14 cells were injected into the pleural cavity of nude mice, and GCV at 50 mg/kg body weight was administered i.p. every 24 hours for 14 days. Next, the survival times of each group of mice were compared using the log-rank test.
Determination of gene transfer efficiency in vivo
To determine the in vivo gene transfer efficiency, 2.0 ϫ 10 6 PC14 cells were transplanted into the pleural cavity of a nude mouse at day 0. Next, the pEGFP-N1 plasmid (Clontech, Palo Alto, Calif), which expresses a red-shifted green fluorescent protein (GFP) mutant, EGFP, under the control of the cytomegalovirus promoter, 19 was transfected by the same protocol as the intrapleural gene transfer of the pCtkN2 plasmid. The mice were sacrificed at day 4. A total of 500 L of phosphatebuffered saline was injected into the pleural cavity for lavage, and the cells and fluid were recovered with a syringe. The cells were analyzed by FACScalibur (Becton Dickinson, San Jose, Calif) with an excitation wavelength of 488 nm. Contaminating red blood cells and inflammatory cells were excluded by size, and dead cells were excluded by propidium iodide staining.
RESULTS
GCV sensitivity of HSV-TK-transduced cells in vitro and in vivo
We first examined GCV sensitivity of the HSV-TKtransduced lung cancer cells. The pCtkN2 vector was transfected into PC14 cells by the liposome-mediated transfection method, and several clones with stable expression of the HSV-TK gene were isolated. Among the clones examined, PC14-TK-14 cells showed the highest level of HSV-TK mRNA expression; PC14-TK-16 cells showed the lowest level. The levels of HSV-TK expression in the cloned cells were in the following order: PC14-TK-14 Ͼ PC14-TK-4 Ͼ PC14-TK-15 Ͼ PC14-TK-1 Ͼ PC14-TK-16 (Table 1) .
We estimated the IC 50 values of these clones and parent PC14 cells for GCV from the GCV dose-response killing curves. The IC 50 value of the parent PC14 cells was Ͼ100 M, whereas those of the PC14-TK-14 cells and the PC14-TK-16 cells were Ͻ0.01 M and 30 M, respectively. These results indicate that cells expressing HSV-TK became sensitive to the cytotoxic activities of GCV in vitro, and the sensitivity was dependent upon the level of HSV-TK expression.
To examine whether these HSV-TK-transduced clones are also sensitive to GCV in vivo, 1 ϫ 10 7 cells were inoculated s.c. into the flanks of nude mice and treated with GCV. Tumor growth was suppressed by GCV in proportion to the level of HSV-TK expression in the cells. In particular, in the case of the PC14-TK-14 cells, which showed the highest level of HSV-TK expression, shrinkage of tumors was observed after 7 days of GCV treatment; the tumors shrank completely on day 19. The animals remained tumor free for Ͼ100 days ( Table 1) .
Effect of GCV treatment on pleural metastasis of HSV-TK-transduced PC14 cells
We subsequently examined the effect of HSV-TK/GCV treatment on the growth of HSV-TK-transduced PC14 cells in the pleural cavity. We used a metastatic model of human NSCLC that had been developed previously in our laboratory. 18 A total of 2 ϫ 10 6 cells were inoculated , and Ͼ120 days, respectively (Fig 2) . Mice with PC14-TK-14 showed significantly prolonged survival rates compared with other groups of mice (P Ͻ .001).
Inhibition of pleural metastasis of PC14 cells by intrapleural lipofection of HSV-TK gene and GCV treatment
The following experiment was performed to evaluate whether direct in vivo lipofection of pCtkN2 followed by GCV treatment can suppress the development of pleural metastasis in the mice. A total of 2 ϫ 10 6 parent PC14 cells were inoculated into the pleural cavity of 15 nude mice. At 24 hours postinoculation, five of the mice were injected in the pleural cavity with the HSV-TK gene expression plasmid as a DNA-liposome complex, and GCV was administered for 8 days. The remaining 10 mice receiving PC14 inoculations constituted two different control groups as follows: Five mice were injected in the pleural cavity three times with DNA-liposome complex followed by an injection of saline instead of GCV for 8 days; the other five mice were not treated at all after the injection of PC14 cells (Fig 1, A-C) . Two of the five mice treated with GCV survived for Ͻ140 days; the other three mice died in ϳ50 -70 days. The mean survival of mice with GCV treatment was 77.2 days, on the assumption that the two surviving mice died in 140 days. In contrast, none of the five mice without treatment and the five mice treated with saline survived Ͼ50 days (Fig 3, exp. 1) . The mean survivals of the notreatment group and the saline-treated group were 25.4 Ϯ 4.6 and 27.0 Ϯ 4.8 days, respectively. There was a significant difference in the prognosis of the mice between the GCV-treated group and the two control groups (P ϭ .03). To confirm the reliability of this study, we performed a second experiment under the same protocol. The survival rates for the mice in the GCVtreated group were again significantly better than those for the mice in the no-treatment and saline-treated groups (P Ͻ .01) (Fig 3, exp. 2) . Thus, the results were reproducible, suggesting the effectiveness of in vivo HSV-TK/GCV therapy for the suppression of NSCLC cell growth in the pleural cavity.
The lack of an assay to accurately quantify the burden of pleural metastasis prompted us to perform autopsies on mice from each of the groups. All animals from the no-treatment group and from the saline-treated group had evidence of tumor burden; however, two of five mice treated with GCV had no tumors in the pleural cavity (Fig 4) . Therefore, the treatment with lipofection-based HSV-TK gene/GCV for pleural metastasis of lung cancer resulted in a dramatic reduction of overall tumor burden.
Bystander effect of GCV treatment on HSV-TKtransfected cells in vitro and in vivo
The efficiency of gene transfer by in vivo lipofection has been considered to be low. 20 However, in our system, the GCV-treated group showed a significantly prolonged survival rate compared with the control groups. Therefore, we quantified the extent of the bystander-mediated cell killing effect in this system. To investigate the bystander effect in vitro, the HSV-TK transduced PC14-TK-14 cells were mixed in varying proportions with the parental PC14 cells prior to GCV treatment. As few as 10% of HSV-TK-transduced cells were sufficient to eradicate the majority of the mixed cell population when the cells were exposed to GCV in vitro (data not shown).
When the mixed cells were injected s.c. to generate tumors, tumors that contained 100% and 33% of PC14-TK-14 cells shrank completely after GCV treatment. Alternatively, the growth rates of tumors with 3.3% and 1% of PC14-TK-14 cells were similar to that of tumors with the parental PC14 cells. A s.c. injection of 10% PC14-TK-14 cells followed by GCV treatment gave rise to tumors that were significantly smaller than parental PC14 tumors (P ϭ .003) ( Table 2 ). These data indicated that 10% of HSV-TK-transduced cells were sufficient to confer a growth suppression of PC14 cells in vivo.
We further investigated the bystander effect of GCV treatment for PC14 cells in the pleural cavity. When the mixed cells were injected intrapleurally to generate tumors in the pleural cavity, the survival rates of mice with tumors that contained Ͼ10% of PC14-TK-14 cells were significantly longer than those of mice with tumors containing parental PC14 cells alone (Fig 5) .
Efficiency of liposome-mediated gene transfer in vivo
In vivo transfection efficiency was evaluated by a fluorescence-activated cell sorter (FACS) analysis using a GFP-expressing plasmid. First, the pEGFP vector was transfected into PC14 cells in vitro. After 60 hours of transfection, the cells were harvested and analyzed by flow cytometry. The gate for the determination of GFP positivity was set using a negative control of untransfected PC14 cells. As shown in Figure 6 , the signal intensity varied among transfected cells, and 42.7% of the cells were regarded as GFP ϩ . Next, the pEGFP vector was transfected into PC14 cells in vivo, and transfected cells were recovered as described in Materials and Methods. Using the same criteria, the efficiency of in vivo gene transfer was determined to be 13.6%. As observed in the cells of in vitro transfection, cells with various levels of signal intensities were present after in vivo transfection, suggesting that the levels of gene expression vary among transfectants by this method. 
DISCUSSION
Here, we demonstrate the effectiveness of in vivo lipofection-based HSV-TK gene therapy for pleural metastasis of NSCLC. Pleural metastasis constructed in nude mice was successfully treated by direct injection of an HSV-TK-expressing plasmid-liposome complex into the pleural cavity followed by systemic GCV administration.
The survival rates in the mice from the GCV-treated group were significantly longer than those in mice from the control groups. Because the pleural cavity is an anatomically closed space, we speculated that the transfection efficiency of lipofection in the pleural cavity is similar to that seen in vitro. Using the pEGFP-N1 plasmid, the transfection efficiency in vitro was determined to be 42.7%, whereas the transfection efficiency in vivo was 13.6%. Thus, the transfection efficiency in vivo was much less than that in vitro. The survival curve of the GCV-treated group was similar to that of the 10% HSV-TK-transduced cells. Thus, we speculate that the in vivo transfection efficiency is ϳ10%. Aoki et al reported that the transfection efficiency of lipofection in the peritoneal cavity was also ϳ10%.
14 Although the pleural cavity is different from the peritoneal cavity in various aspects, the transfection efficiency of intrapleural lipofection appeared to be similar to the efficiency of i.p. lipofection. Although the transfection efficiency of lipofection in the pleural cavity was low, both in vitro and in vivo experiments using HSV-TK-transduced and untransduced cells suggested that, due to the bystander effect, 10% of transduced cells are sufficient for a growth suppression of PC14 cells by GCV treatment. Thus, it is plausible that 10% of HSV-TK ϩ cells are significant enough for HSV-TK-mediated cell killing in vivo due to the bystander effect. 21 However, we should also consider another possibility for the significant growth suppression of PC14 cells in the pleural cavity. It is possible that the transfected gene was expressed at low levels in most cells, because the flow cytometric analysis indicated the presence of cells with various levels of gene expression after intrapleural lipofection.
We tested the feasibility of direct intrapleural lipofection in vivo using two other NSCLC cell lines, A549 and H157; however, the survival rates in mice from the GCV-treated group were not significantly greater than those in mice from the control groups. Because the transfection efficiencies of those cell lines in vitro were much lower than that of PC14 cells, it was suggested that the transfection efficiency of intrapleural lipofection differs among different cancer cells. We should also consider the difference in the efficiency of the bystander effect among cancer cells. Thus, this method would be applicable only to lung cancer cells with high efficiencies of gene transfer and of the bystander effect. Curiel et al reported that a problem of gene therapy for lung diseases was the ability to transduce high percentages of cells. 22 Therefore, a more effective method of gene transfer needs to be developed so that this method can regularly be used for the treatment of pleural metastasis.
Various agents have been instilled into the pleural space to treat malignant pleural effusions, and agents such as talc, tetracycline, and bleomycin effectively create a chemical pleuritis. 3 However, when we dissected the surviving mice from the GCV-treated group, overt pleuritis was not observed, suggesting the safety of this method for the treatment of pleural metastasis. Previously, Kucharczuk et al also reported the safety of intrapleural administration of a replication-deficient recombinant adenovirus harboring the HSV-TK gene followed by systemic GCV therapy in baboons. 23 However, because the nude mice used in this study are immunosuppressed, further studies are required to clarify the safety and toxicity of this method.
A number of gene delivery techniques have been developed and can be grouped into nonviral and virusmediated gene transfer systems. Each of these systems has advantages and disadvantages. Cationic liposomes have no acute toxicity or immune reactions such as those experienced for adenovirus vectors; thus, multiple injections of a cationic liposome will be less problematic than those of viral vectors. 24 -28 Because multiple injections will be required to treat pleural metastasis completely, we used cationic liposomes as a method for the in vivo delivery of therapeutic genes. We examined the therapeutic feasibility of multiple injections of HSV-TK expression plasmid-liposome complex for a total of three times at 24-hour intervals biweekly. However, the survivals rates in mice from the GCV-treated group were not significantly better than those in mice from the control groups, and therapeutic death of mice was observed due to the toxicity of GCV (data not shown). Further modification of this system will be necessary before it can be applied for the treatment of patients with NSCLC.
Because the mean survival of mice receiving intrapleural injection of PC14 cells was Յ30 days, 18 this PC14 model would reflect the advanced stages of lung cancer. A patient with a malignant pleural effusion is classified into stage IIIB or stage IV, and these groups of patients account for Ͼ50% of the NSCLC population. 2 The average survival time of patients classified as stage IIIB and stage IV is still Յ6 months. 29 Roth et al reported direct i.t. injection methods with a retroviral or adenoviral vector for the treatment of advanced stage lung cancer. 16 -17 In this study, we targeted only pleural metastasis of lung cancer, treated them by an injection of an HSV-TK-expressing plasmid-liposome complex into the pleural cavity. Because this technique is easy to perform and could be used repeatedly, it is possible that a combination therapy of an i.t. injection with an intrapleural injection could further contribute to prolonging the survival time of a patient and to improving the quality of life of a patient. This preclinical study suggests the therapeutic feasibility of an in vivo lipofection-based suicidal gene/prodrug strategy for pleural metastasis of lung cancer.
